87 related articles for article (PubMed ID: 15294455)
41. Bcl-2 down-regulation is a novel mechanism of paclitaxel resistance.
Ferlini C; Raspaglio G; Mozzetti S; Distefano M; Filippetti F; Martinelli E; Ferrandina G; Gallo D; Ranelletti FO; Scambia G
Mol Pharmacol; 2003 Jul; 64(1):51-8. PubMed ID: 12815160
[TBL] [Abstract][Full Text] [Related]
42. ETS1 promotes chemoresistance and invasion of paclitaxel-resistant, hormone-refractory PC3 prostate cancer cells by up-regulating MDR1 and MMP9 expression.
Kato T; Fujita Y; Nakane K; Kojima T; Nozawa Y; Deguchi T; Ito M
Biochem Biophys Res Commun; 2012 Jan; 417(3):966-71. PubMed ID: 22206665
[TBL] [Abstract][Full Text] [Related]
43. Cell cycle checkpoint efficiency and cellular response to paclitaxel in prostate cancer cells.
Lanzi C; Cassinelli G; Cuccuru G; Supino R; Zuco V; Ferlini C; Scambia G; Zunino F
Prostate; 2001 Sep; 48(4):254-64. PubMed ID: 11536305
[TBL] [Abstract][Full Text] [Related]
44. C-MYC modulation induces responsiveness to paclitaxel in adrenocortical cancer cell lines.
Cerquetti L; Sampaoli C; De Salvo M; Bucci B; Argese N; Chimento A; Vottari S; Marchese R; Pezzi V; Toscano V; Stigliano A
Int J Oncol; 2015 May; 46(5):2231-40. PubMed ID: 25708932
[TBL] [Abstract][Full Text] [Related]
45. MYC prevents apoptosis and enhances endoreduplication induced by paclitaxel.
Gatti G; Maresca G; Natoli M; Florenzano F; Nicolin A; Felsani A; D'Agnano I
PLoS One; 2009; 4(5):e5442. PubMed ID: 19421315
[TBL] [Abstract][Full Text] [Related]
46. Cellular models of drug- and radiation-resistant small cell lung cancer.
Davey RA; Locke VL; Henness S; Harvie RM; Davey MW
Anticancer Res; 2004; 24(2A):465-71. PubMed ID: 15152945
[TBL] [Abstract][Full Text] [Related]
47. Resistance to apoptosis of harringtonine-resistant HL60 cells induced by tetrandrine.
He QY; Zhang HQ; Pang DB; Chi XS; Xue SB
Zhongguo Yao Li Xue Bao; 1996 Nov; 17(6):545-9. PubMed ID: 9863153
[TBL] [Abstract][Full Text] [Related]
48. Synergy of 5-aza-2'-deoxycytidine (DAC) and paclitaxel in both androgen-dependent and -independent prostate cancer cell lines.
Shang D; Liu Y; Liu Q; Zhang F; Feng L; Lv W; Tian Y
Cancer Lett; 2009 Jun; 278(1):82-7. PubMed ID: 19168279
[TBL] [Abstract][Full Text] [Related]
49. Differential sensitivity to paclitaxel-induced apoptosis and growth suppression in paclitaxel-resistant cell lines established from HEC-1 human endometrial adenocarcinoma cells.
Tanaka T; Toujima S; Tanaka J
Int J Oncol; 2012 Nov; 41(5):1837-44. PubMed ID: 22923148
[TBL] [Abstract][Full Text] [Related]
50. Apigenin induces c-Myc-mediated apoptosis in FRO anaplastic thyroid carcinoma cells.
Kim SH; Kang JG; Kim CS; Ihm SH; Choi MG; Yoo HJ; Lee SJ
Mol Cell Endocrinol; 2013 Apr; 369(1-2):130-9. PubMed ID: 23376608
[TBL] [Abstract][Full Text] [Related]
51. Camptothecin-induced apoptosis is enhanced by Myc and involves PKCdelta signaling.
Albihn A; Mo H; Yang Y; Henriksson M
Int J Cancer; 2007 Oct; 121(8):1821-9. PubMed ID: 17565738
[TBL] [Abstract][Full Text] [Related]
52. Mechanism of paclitaxel resistance in a human prostate cancer cell line, PC3-PR, and its sensitization by cabazitaxel.
Sobue S; Mizutani N; Aoyama Y; Kawamoto Y; Suzuki M; Nozawa Y; Ichihara M; Murate T
Biochem Biophys Res Commun; 2016 Oct; 479(4):808-813. PubMed ID: 27687545
[TBL] [Abstract][Full Text] [Related]
53. Modulation of the sphingolipid rheostat is involved in paclitaxel resistance of the human prostate cancer cell line PC3-PR.
Aoyama Y; Sobue S; Mizutani N; Inoue C; Kawamoto Y; Nishizawa Y; Ichihara M; Kyogashima M; Suzuki M; Nozawa Y; Murate T
Biochem Biophys Res Commun; 2017 Apr; 486(2):551-557. PubMed ID: 28322796
[TBL] [Abstract][Full Text] [Related]
54. Proteomic Profiling of Paclitaxel Treated Cells Identifies a Novel Mechanism of Drug Resistance Mediated by PDCD4.
Xu H; Dephoure N; Sun H; Zhang H; Fan F; Liu J; Ning X; Dai S; Liu B; Gao M; Fu S; Gygi SP; Zhou C
J Proteome Res; 2015 Jun; 14(6):2480-91. PubMed ID: 25928036
[TBL] [Abstract][Full Text] [Related]
55. HMGB1 release promotes paclitaxel resistance in castration-resistant prostate cancer cells via activating c-Myc expression.
Lei X; Hu X; Zhang T; Zhang J; Wu C; Hong W; Jiang Y; Wang Q; Xie Y; Zhao Y; Zhou J; Jin F; Yu W; Guo B; Bai H; Zhang Q
Cell Signal; 2020 Aug; 72():109631. PubMed ID: 32275943
[TBL] [Abstract][Full Text] [Related]
56. Multiple effects of paclitaxel are modulated by a high c-myc amplification level.
Bottone MG; Soldani C; Tognon G; Gorrini C; Lazzè MC; Brison O; Ciomei M; Pellicciari C; Scovassi AI
Exp Cell Res; 2003 Oct; 290(1):49-59. PubMed ID: 14516787
[TBL] [Abstract][Full Text] [Related]
57. AKT/ERK activation is associated with gastric cancer cell resistance to paclitaxel.
Wu G; Qin XQ; Guo JJ; Li TY; Chen JH
Int J Clin Exp Pathol; 2014; 7(4):1449-58. PubMed ID: 24817940
[TBL] [Abstract][Full Text] [Related]
58. Paclitaxel-induced FasL-independent apoptosis and slow (non-apoptotic) cell death.
Blagosklonny MV; Robey R; Sheikh MS; Fojo T
Cancer Biol Ther; 2002; 1(2):113-7. PubMed ID: 12170770
[TBL] [Abstract][Full Text] [Related]
59. Taxanes.
Sackett D; Fojo T
Cancer Chemother Biol Response Modif; 1997; 17():59-79. PubMed ID: 9551209
[No Abstract] [Full Text] [Related]
60. Hyperthermic enhancement of the apoptotic and antiproliferative activities of paclitaxel.
Othman T; Goto S; Lee JB; Taimura A; Matsumoto T; Kosaka M
Pharmacology; 2001 May; 62(4):208-12. PubMed ID: 11359996
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
